Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 75 25 versus NOVOLOG MIX 70 30 FLEXPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 75 25 versus NOVOLOG MIX 70 30 FLEXPEN.
HUMALOG MIX 75/25 vs NOVOLOG MIX 70/30 FLEXPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biphasic insulin analog combining rapid-acting insulin lispro (25%) and intermediate-acting insulin lispro protamine suspension (75%). Insulin lispro lowers blood glucose by binding to insulin receptors, facilitating cellular glucose uptake, inhibiting hepatic gluconeogenesis, and promoting glycogenesis and lipogenesis.
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It replaces endogenous insulin and has a faster onset and shorter duration than regular human insulin due to altered amino acid sequence (substitution of proline at position 28 with aspartic acid).
Subcutaneous injection: 75% insulin lispro protamine suspension and 25% insulin lispro solution. Dose individualized based on glycemic goals and prior insulin regimen. Typical total daily dose: 0.5-1 unit/kg/day divided into two doses (pre-breakfast and pre-dinner).
Subcutaneous injection only. Initial total daily insulin dose: 0.5 to 1 unit/kg/day. Administer 70% intermediate-acting insulin aspart protamine and 30% rapid-acting insulin aspart. Typically given twice daily within 15 minutes before meals. Dose individualize based on glycemic goals.
None Documented
None Documented
Insulin lispro: 0.5-1 hour; protamine-bound fraction prolongs absorption, resulting in a biphasic profile with an effective half-life of 2-4 hours for the 75% NPL component.
0.5-1 hour for the rapid-acting insulin aspart component and 8-10 hours for the protamine-crystallized insulin aspart component. Clinical context: biphasic profile allows for both prandial and basal coverage.
Renal: 60-80% as unchanged drug following subcutaneous absorption; the remaining fraction undergoes hepatic metabolism and biliary/fecal excretion.
Renal elimination of degradation products. Approximately 30-40% of insulin dose is excreted unchanged in urine; the remainder is metabolized primarily in liver and kidney and excreted as metabolites.
Category C
Category C
Insulin Analog
Insulin Analog